Shruti Bhat PhD, MBA, Operations Excellence Expert
  • Home
  • Operational Excellence
  • Business Continuity
  • Case Studies
  • Books
  • Insights
  • Engage Shruti
    • PharmaOps Consulting
    • Tara LeanWorks
    • Training Services
  • Blog
  • Whitepapers
  • Checklists and Templates
  • Free eBooks
  • Videos
  • Articles
    • Process Improvement
    • Business Transformation
    • Innovation Management
    • Leading Research and Development
    • Developer's Diary
    • Change Management
    • Digital Transformation
    • Quality Improvement
  • About Shruti
  • Contact

Australian Innovation Patent Advantage - Ignore it at Your Potential Peril

2/25/2010

0 Comments

 
The Australian patent system has a unique beast called the "innovation patent". Under the Australian patent system it is possible to obtain both standard patents and innovation patents. Under the innovation patent system, while the term is only eight years, there is no test for obviousness, but rather a test for "innovative step". Further, in certain circumstances, it is possible to file innovation patents from standard patents and vice versa.

The lack of an obviousness test provides a great opportunity for patentees to take advantage of our innovation patent as a powerful strategic property in its own right and/or to maximise their advantage during litigation. Such was the case in Dura-Post (Aust) Pty Ltd v Delnorth Pty Ltd [2009] FCAFC 81, where the Full Federal Court recently decided to uphold a trial judge's decision that an innovation patent was not subject to an obviousness test, but rather to the substantially weaker "innovative step" test being something peculiar to Australian jurisprudence.

In the Dura-Post case, relating to the simple subject matter of elastically-deformable road-side posts, the patentee had filed multiple divisional innovation patents from a standard patent and successfully sued on the innovation patents. The successful innovation patent claims each defined a new, but arguably non-inventive, combination of known features. However, the Court concluded, based on evidence, that in each case the claimed difference over the prior art, while small, did provide a substantial or "real" contribution to the working of the invention and as such passed the threshold test.

The implications and recommendations

The absence of an obviousness test allows applicants to potentially obtain protection for more marginal developments and/or obtain broader rights for an invention in Australia than would be possible in nearly all other jurisdictions. As such, we would encourage potential applicants to consider innovation patents as an adjunct to a standard patent application in order to obtain a fast-to-grant right with potentially broader claims.

They should also be considered as an adjunct or alternative for developments that would normally at best be protected via the useful, but limited, registered designs regime. Importantly, many applicants are already doing this. It is undoubtedly preferable to be the holder of innovation patents in your particular IP space, than trying to operate around competitors' rights which may prove to be unexpectedly broad and difficult to successfully challenge.


Innovation patents proceed to "grant" with only basic formalities review. They need not be examined substantively unless and until the patentee wishes to establish enforceable rights. In this way, they can be both powerful and flexible, as it is clear from this latest case that minor points of distinction disclosed within the specification may be sufficient to establish patentable rights.

For the same reasons, it is difficult to accurately predict the potential scope of granted but unexamined innovation patents of third parties. This arguably provides an added incentive for applicants to attempt to dominate particular market sectors through innovation patents.

However, it is worth noting that the innovation patent regime appears to be at odds with one of IP Australia's stated goals, of aligning Australian patentability standards with those of other major jurisdictions such as Europe and the US. Such policy considerations may give rise to a substantive review or revision of the regime in due course, although any resultant changes would almost certainly not have retrospective effect.

Meanwhile, based on the law as it presently stands, a good option is to take full advantage of the significant strategic and commercial benefits that innovation patents currently provide. Your competitors may already be doing just that!

​Disclaimer- In addition to Terms and Conditions of this blog, the content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
​


Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    New Book Released!

    Revolutionizing Industries with Lean Six Sigma

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    Agile
    Artificial Intelligence
    Automation
    Biotechnology
    Books
    Business Continuity
    Business Turnaround
    Case Studies
    Change Management
    Checklists
    Chemical Industry
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    Insights
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    MSMEs
    Nanotechnology
    Operational Excellence
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    R&D Leadership
    Robotics
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    Templates
    TQM
    Videos
    Voice Of Customer
    Whitepaper
    Workshops

    Shruti's books...

    Picture
    top ten strategic decision-making tools for operational excellence
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    how to lead a successful business transformation
    leading organizations through crisis
    emotional intelligence
    how to overcome challenges of creating effective teams
    modular kaizen Vs Blitz kaizen
    How to increase employee engagement as a new boss

Connect with Dr. Shruti Bhat at- ​YouTube, LinkedIn​ and X

© Copyright 1992- 2026 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
Picture
Subscribe to PharmaOps Consulting YouTube Channel
Subscribe to Operational Excellence Academy YouTube Channel
​Subscribe to Operational Excellence Academy YouTube Channel
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media